The First-MIND trial, it’s a Phase Ib study that tested the combination of rituximab-CHOP plus tafasitamab or rituximab-CHOP and tafasitamab-lenalidomide. Tafasitamab is the new anti-CD19 engineered antibody and has been added to R-CHOP in first line in diffuse large B cell lymphoma. The main protocols of this study was to prepare the background for the large Phase III randomized Front-MIND study...
The First-MIND trial, it’s a Phase Ib study that tested the combination of rituximab-CHOP plus tafasitamab or rituximab-CHOP and tafasitamab-lenalidomide. Tafasitamab is the new anti-CD19 engineered antibody and has been added to R-CHOP in first line in diffuse large B cell lymphoma. The main protocols of this study was to prepare the background for the large Phase III randomized Front-MIND study.
In that study, we tested 66 patients, and the patients received R-CHOP and tafasitamab or R-CHOP and tafasitamab-lenalidomide. Overall, the efficacy of the combination is quite good, with more than 80% of complete response rate that were evaluated by PET and progression-free survival that is around 75% at two years. The safety, that was the main purpose of the study, was reasonably good because the main toxicity was myelotoxicity, a little bit higher than R-CHOP alone, but was manageable. So this was done just to prepare the Front-MIND study that is a randomized study.